

AMENDMENTS TO THE CLAIMS

The following listing of claims will replace all prior versions, and listings, of claims in the application.

- 1-39. (canceled)
40. (Currently Amended) A composition for treating inflammatory components of a hormonally-dependent cancer, comprising, in therapeutically effective amounts, a sulfated proteoglycan, one or more flavonoid compounds, one or more isoflavonoid compounds, and olive kernel extract, wherein the ratio of the sulfated proteoglycan to the flavonoid ranges from 1:5 to 12:1, the ratio of the sulfated proteoglycan to the isoflavonoid ranges from 1:20 to 6:1, and the ratio of the sulfated proteoglycan to the olive kernel extract ranges from 1:24 to 6:7, and wherein the olive kernel extract is unrefined and has oleic acid-related acidity <3% and water content <1%.
41. (Previously Presented) The composition of claim 40, further comprising a chemotherapeutic agent.
42. (Previously Presented) The composition of claim 41, wherein said proteoglycan is chondroitin sulfate, said flavonoid compound is quercetin, said isoflavonoid compound is phenoxodiol or genistein, and said chemotherapeutic agent is tamoxifen or raloxifen.
43. (Previously Presented) The composition of claim 40, comprising, in mg, chondroitin sulfate, 50-300; olive kernel extract, 350-1200; quercetin, 25-250; phenoxodiol isoflavone, 500-1000; and genistein, 50-300.
44. (Previously Presented) The composition of claim 42, wherein said tamoxifen or raloxifen is in the amount of 10 mg.
45. (Withdrawn) A method of treating the inflammatory components of a hormonally-dependent cancer, comprising the oral administration of a composition of claim 40.
46. (Withdrawn) A method of treating both the inflammatory components and the growth components of a hormonally-dependent cancer, comprising the administration of the composition of claim 42.

47. (Withdrawn) A method of treating the inflammatory components of a hormonally-dependent cancer, comprising the oral administration of a composition of claim 43.
48. (Withdrawn) A method of treating both the inflammatory components and the growth components of a hormonally-dependent cancer, comprising the administration of the composition of claim 44.
49. (Previously Presented) The composition of claim 40, wherein said cancer is selected from the group consisting of breast cancer, ovarian cancer, pancreatic cancer, testicular cancer, prostate cancer, pituitary cancer, endometrial cancer, and melanoma.
50. (Previously Presented) The composition of claim 40, comprising therapeutically effective amounts of chondroitin sulfate, olive kernel extract, phenoxodiol isoflavone, quercetin, and genistein.
51. (Previously Presented) The composition of claim 50, wherein the chondroitin sulfate is non-bovine chondroitin sulfate.
52. (Currently Amended) The composition of claim 51, further comprising a therapeutically effective amount of tamoxifen or raloxifen.
53. (Currently Amended) A composition for treating a hormonally-dependent cancer, comprising, in therapeutically effective amounts, a sulfated proteoglycan, one or more flavonoid compounds, one or more isoflavonoid compounds, olive kernel extract, and a chemotherapeutic agent, wherein the ratio of the sulfated proteoglycan to the flavonoid ranges from 1:5 to 12:1, the ratio of the sulfated proteoglycan to the isoflavonoid ranges from 1:20 to 6:1, the ratio of the sulfated proteoglycan to the olive kernel extract ranges from 1:24 to 6:7, and the ratio of the sulfated proteoglycan to the chemotherapeutic agent ranges from 5:1 to 30:1, and wherein the olive kernel extract is unrefined and has oleic acid-related acidity <3% and water content <1%.
54. (Previously Presented) The composition of claim 53, wherein said proteoglycan is chondroitin sulfate, said flavonoid compound is quercetin, said isoflavonoid compound is phenoxodiol, and said chemotherapeutic agent is tamoxifen or raloxifen.

55. (Previously Presented) The composition of claim 53, comprising, in mg, non-bovine chondroitin sulfate, 50-300; olive kernel extract, 350-1200; quercetin, 25-250; phenoxodiol isoflavone, 500-1000; genistein, 50-300; and tamoxifen, 10.
56. (Canceled)
57. (Previously Presented) The composition of claim 53, wherein said cancer is selected from the group consisting of breast cancer, ovarian cancer, pancreatic cancer, testicular cancer, prostate cancer, pituitary cancer, endometrial cancer, and melanoma.
58. (Previously Presented) The composition of claim 53, comprising therapeutically effective amounts of chondroitin sulfate, olive kernel extract, phenoxodiol isoflavone, quercetin, and genistein.
59. (Previously Presented) The composition of claim 58, wherein the chondroitin sulfate is non-bovine chondroitin sulfate.
60. (Previously Presented) The composition of claim 59, wherein the chemotherapeutic agent is a therapeutically effective amount of tamoxifen or raloxifen.
61. (Currently Amended) The composition of claim 53, comprising, in mg, non-bovine chondroitin sulfate, 50-300; olive kernel extract, ~~450-600~~350-1200; quercetin, ~~500-4000~~25-250; phenoxodiol isoflavone, ~~25-250~~500-1000; and genistein, 50-300; and raloxifen, 10.